Home
About
Overview
Sharing Data
ORCID
Help
History (118)
Safety-Based Medical Device Withdrawals
Impaired peroxisomal function in the central nervous system with inflammatory disease of experimental autoimmune encephalomyelitis animals and protection by lovastatin treatment.
Bedtime ranitidine does not eliminate the need for a second daily dose of omeprazole to suppress nocturnal gastric pH.
Psychiatric Status Rating Scales
Galantamine prolonged-release formulation in the treatment of mild to moderate Alzheimer's disease.
See All 118 Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Galantamine prolonged-release formulation in the treatment of mild to moderate Alzheimer's disease.
Galantamine prolonged-release formulation in the treatment of mild to moderate Alzheimer's disease. Dement Geriatr Cogn Disord. 2005; 20(2-3):120-32.
View in:
PubMed
subject areas
Activities of Daily Living
Aged
Aged, 80 and over
Alzheimer Disease
Behavior
Cholinesterase Inhibitors
Delayed-Action Preparations
Double-Blind Method
Endpoint Determination
Female
Galantamine
Humans
Male
Middle Aged
Psychiatric Status Rating Scales
authors with profiles
Michael R. Gold